"The Rand Eye Institute is a leader in LASER Vision Correction, Cataract Eye Surgery and No-Flap LASIK for over 40 years. We offer State of the Art services for the majority of Eye Conditions utilizing the most advanced technology. Rand Eye Institute’s doctors are at the forefront of high definition custom cataract surgical procedures, and are recognized leaders in advanced laser cataract surgery. Highly regarded as one of the finest surgical facilities in the south Florida area, our surgical pavilion is licensed by the state of Florida, inspected and certified by the Joint Commission on hospital accreditation."

During the past decade, Rand Eye conducted 23 clinical trials. In the 10-year time frame, 23 clinical trials started and 4 clinical trials were completed, i.e. on average, 17.4% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 4 clinical trials were completed. i.e. 22.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Rand Eye" #1 sponsor was "Hoffmann-La Roche" with 10 trials, followed by "Kodiak Sciences Inc" with 4 trials sponsored, "Genentech, Inc." with 3 trials sponsored, "Aerpio Therapeutics" with 1 trials sponsored and "Bayer" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Rand Eye" #1 collaborator was "Chugai Pharmaceutical" with 1 trials as a collaborator, "Novartis Pharmaceuticals" with 1 trials as a collaborator and "Regeneron Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Rand Eye" are "Diabetic Macular Edema" (5 trials), "Geographic Atrophy" (4 trials), "Macular Degeneration, Age-Related" (3 trials), "Macular Edema" (2 trials) and "Neovascular Age-related Macular Degeneration" (2 trials). Many other conditions were trialed in "Rand Eye" in a lesser frequency.

Most popular intervention types in "Rand Eye" are "Drug" (21 trials), "Other" (9 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (11 trials), "Aflibercept" (7 trials), "Faricimab" (7 trials), "KSI-301" (4 trials) and "Ranibizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Rand Eye" are 23 trials for "All" genders.

Currently, there are NaN active trials in "Rand Eye". undefined are not yet recruiting, 2 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Rand Eye, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Rand Eye, 0 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".